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IN-DEPTH REVIEW
Cholesterol Crystal Embolism: A Recognizable Cause
of Renal Disease
Francesco Scolari, MD, Regina Tardanico, MD, Roberta Zani, MD, Alessandra Pola, MD,
Battista Fabio Viola, MD, Ezio Movilli, MD, and Rosario Maiorca, MD
c Cholesterol crystal embolism, sometimes separately designated atheroembolism, is an increasing and still
underdiagnosed cause of renal dysfunction antemortem in elderly patients. Renal cholesterol crystal embolization,
also known as atheroembolic renal disease, is caused by showers of cholesterol crystals from an atherosclerotic
aorta that occlude small renal arteries. Although cholesterol crystal embolization can occur spontaneously, it is
increasingly recognized as an iatrogenic complication from an invasive vascular procedure, such as manipulation
of the aorta during angiography or vascular surgery, and after anticoagulant and fibrinolytic therapy. Cholesterol
crystal embolism may give rise to different degrees of renal impairment. Some patients show only a moderate loss
of renal function; in others, severe renal failure requiring dialysis ensues. An acute scenario with abrupt and sudden
onset of renal failure may be observed. More frequently, a progressive loss of renal function occurs over weeks. A
third clinical form of renal atheroemboli has been described, presenting as chronic, stable, and asymptomatic renal
insufficiency. The renal outcome may be variable; some patients deteriorate or remain on dialysis, some improve,
and some remain with chronic renal impairment. In addition to the kidneys, atheroembolization may involve the
skin, gastrointestinal system, and central nervous system. Renal atheroembolic disease is a difficult and controver-
sial diagnosis for the protean extrarenal manifestations of the disease. In the past, the diagnosis was often made
postmortem. However, in the last decade, awareness of atheroembolic renal disease has improved, enabling us to
make a correct premortem diagnosis in a number of patients. Correct diagnosis requires the clinician to be alert to
the possibility. The typical patient is a white man aged older than 60 years with a baseline history of hypertension,
smoking, and arterial disease. The presence of a classic triad characterized by a precipitating event, acute or
subacute renal failure, and peripheral cholesterol crystal embolization strongly suggests the diagnosis. The con-
firmatory diagnosis can be made by means of biopsy of the target organs, including kidneys, skin, and the gastrointesti-
nal system. Thus, Cinderella and her shoe now can be well matched during life. Patients with renal atheroemboli have a
dismal outlook. A specific treatment is lacking. However, it is an important diagnosis to make because it may save
the patient from inappropriate treatment. Finally, recent data suggest that an aggressive therapeutic approach with
patient-tailored supportive measures may be associated with a favorable clinical outcome.
© 2000 by the National Kidney Foundation, Inc.
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CHOLESTEROL crystal embolism, some-times separately designated atheroembo-
lism, is a multisystemic disorder that generally
affects many organs. It is characterized by the
occlusion of small arteries by cholesterol crystal
emboli deriving from eroded atherosclerotic
plaques of the aorta or large feeder arteries.1-6 It
is often stated that cholesterol crystal embolism
was first described more than 100 years ago by
the German pathologist, Panum.7 However, the
first reliable description of this disease was made
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by Flory8 in 1945. Subsequently, it evolved slowly
from a pathological curiosity to a clinical en-
tity.1-3 The proximity of the kidneys to the ab-
dominal aorta and the large renal blood supply
make the kidney a frequent target organ for
atheroemboli.
However, cholesterol crystal embolization has
been frequently overlooked as a cause of renal
dysfunction during life. In the past, the diagnosis
of renal cholesterol crystal embolization, also
designated atheroembolic renal disease, often
was made postmortem.1-3 For this reason, the
disorder has been called the Cinderella of nephrol-
ogy: Cinderella (the patient and clinical findings)
and her shoe (the final diagnosis of atheroem-
bolic renal disease) are not usually matched in
life.9,10 However, in the last few years, large
retrospective clinical studies have increased our
understanding of atheroembolic renal disease.11-14
Better knowledge of the disease now permits a
correct premortem diagnosis in a significant num-
ber of cases: Cinderella and her shoe now can be
well matched during life.
The purpose of this review is to discuss the
pathogenesis and incidence of atheroembolic re-
nal disease, its clinical and pathological findings,
and the potential for a correct premortem diag-
nosis.
PATHOGENESIS
The Aorta in Atheroembolic Renal Disease
The hypothesis that cholesterol crystal embo-
lism may originate from a diseased atheroscle-
rotic aorta was first made by Flory8 in 1945.
Among 267 consecutive autopsies, he observed
nine instances of cholesterol crystal embolism:
none in 63 cases in which aortic plaque ulcer-
ation was absent, two instances in 147 cases
(1%) with moderate aortic plaque erosion, and
seven instances in 57 cases (12%) with severe
aortic plaque ulceration. Since then, other inves-
tigators have confirmed the strict correlation of
cholesterol crystal embolism with the severity of
atherosclerotic aortic plaque erosion. In patients
who died with cholesterol crystal emboli syn-
drome, autopsy findings usually showed the inter-
nal lining of the aorta as irregularly ulcerated and
extensively covered by soft, friable, thrombotic
material; in many areas, the soft, friable, yellow
contents of the inner core of the atherosclerotic
lesion communicated with the aortic lumen.15-17
Thus, available data suggest that severe ulcer-
ated atherosclerosis is primarily responsible for
the atheroembolic renal disease. This is fur-
ther supported by the finding that risk factors
for the development of atherosclerosis, such as
older age, male sex, diabetes, hypertension, and
cigarette smoking, are the same risk factors for
developing atheroembolic renal disease (Ta-
ble 1).
Precipitating Factors
The formation of a complicated lesion of ath-
erosclerosis is a prerequisite for the development
of cholesterol crystal emboli syndrome. In the
past decade, our understanding of plaque biologi-
cal characteristics has increased dramatically,
and the concept of vulnerable atherosclerotic
plaque has emerged.18 Atherosclerotic plaques
consist of a fibrous cap, under which are macro-
phages, necrotic debris, and cholesterol crystals.
Plaques with a large extracellular lipid-rich core
and a thin fibrous cap appear to be most vulner-
able to rupture. Mechanical and hemodynamic
stresses may fatigue and weaken the fibrous cap,
which ultimately may rupture, releasing the un-
derlying extracellular cholesterol-rich matrix.
Atheroembolization may occur spontaneously or
after aortic wall trauma, including vascular sur-
gery and angiographic procedures. Other etio-
logic factors include anticoagulation and throm-
bolysis. A number of patients may experience
multiple triggering factors, such as a combina-
tion of anticoagulation, angiographic proce-
dures, and vascular surgery.1-6,11-14,19,20
Vascular surgery procedures known to precipi-
tate cholesterol crystal embolism include abdomi-
nal aortic aneurysm resection and graft, aor-
toiliac and aortofemoral bypass, carotid
endarterectomy, cardiac surgery, and renal artery
Table 1. Atheroembolic Renal Disease: Risk Factors
and Prior Medical Problems
Risk Factors Prior Medical Problems
Male sex Ischemic cardiovascular disease
Age .60 y Cerebrovascular disease
White race Abdominal aortic aneurysm
Hypertension Ischemic nephropathy
Tobacco use Peripheral vascular disease
Diabetes mellitus
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grafts. Vascular surgery may disrupt plaques when
incisions are made through the walls of the
vessel or when the vessel is cross-clamped or
manipulated during surgery.1-6 The occurrence of
atheroemboli may be observed after radiological
instrumentation of the aorta, such as aortogra-
phy, coronary angiography, cardiac catheteriza-
tion, and percutaneous transluminal angioplasty
of the coronary bed, renal arteries, or other
arterial systems. The proposed mechanism is
mechanical trauma. Catheter manipulations
scrape the walls of the aorta, disrupting athero-
sclerotic plaques and exposing the soft, choles-
terol-laden core of the plaque to the arterial
circulation.1-6
Coronary angiography is considered the most
common arteriographic procedure inciting choles-
terol crystal embolism.1-6,11-14 Because atheroscle-
rotic plaques are most common in the abdominal
aorta, some investigators suggest using the bra-
chial approach when there is evidence of severe
aortic atherosclerosis. However, a recent prospec-
tive study of 1,579 patients undergoing coronary
angioplasty did not show significant differences
between the brachial and femoral approaches.21
However, an important limitation of this study
was the low number of events, because only one
patient developed atheroembolization. Thus,
whether the use of the brachial approach is
associated with a lower incidence of atheroem-
boli is still a matter of controversy.
The third precipitating factor described is anti-
coagulant treatment, including both heparin and
oral anticoagulants (warfarin [Coumadin; Du-
Pont Pharma, Wilmington, DE]). These agents
may prevent the formation of a protective throm-
bus overlying an ulcerated plaque or may initiate
the disruption of a complex plaque by causing
hemorrhage into it.1-6 With the advent of throm-
bolytic therapy for the treatment of myocardial
infarction, there have been several case reports in
which the precipitating factor has been the use of
these agents.19 The effect of thrombolytic therapy
is to actively lyse thrombi, including those cover-
ing atherosclerotic plaques. Despite this, athero-
embolism is a complication usually ignored in
the megatrials of thrombolytic therapy of acute
myocardial infarction.22 In 1995, Blankenship et
al,23 in a prospective study, did not show a
significantly greater prevalence of cholesterol
crystal embolism in patients administered throm-
bolytic therapy than in those treated conserva-
tively. However, the study had a small sample
size (60 patients). In addition, the patients under-
went cardiac catheterization before surgery, which
can itself promote atheroembolization. Thus,
larger studies are needed to find or exclude a
relation between thrombolytic therapy and cho-
lesterol crystal embolization.
In early reports, a greater percentage of pa-
tients with atheroembolic renal disease (range,
40% to 69%) showed a spontaneous form of
disease.1-3 However, in more recent reports, cho-
lesterol crystal embolization was much more
frequently associated with precipitating fac-
tors.11-14 This may reflect the increased use of
arterial invasive procedures and the widespread
use of anticoagulation and thrombolysis.
Our own data confirm the growing role of
invasive procedures and anticoagulation as a
triggering factor. From 1989 to 1999, a total of
52 patients (44 men, 8 women; average age, 68
years) with a diagnosis of atheroembolic renal
disease were collected at our institution. The
disease was spontaneous in 11 patients (21%),
and a triggering factor was identified in 41 pa-
tients (79%). Aortic surgery, consisting of aneu-
rysm resection, was the precipitating factor in 8
patients (15%). Twenty-six patients (50%) devel-
oped renal atheroembolism after angiography.
Aortic or coronary angiography through the femo-
ral artery was the sole triggering factor in 16
patients. Angiography was followed by an angio-
plastic procedure in 6 patients (4 patients, renal
artery; 2 patients, coronary artery); in 2 of these
patients, an interventional radiological proce-
dure was completed by stenting. In 4 more pa-
tients, angiography was followed by exposure to
an additional inciting factor: aortic surgery in 3
patients and thrombolytic therapy in 1 patient.
Finally, in 11 patients (21%), the triggering fac-
tor was anticoagulant treatment, including throm-
bolytic therapy, calcic heparin, and oral antico-
agulants.
FATE OF ATHEROEMBOLI
Once in the circulation, cholesterol crystal
emboli lodge in small arteries 150 to 200 mm in
diameter. The lodgment of cholesterol clefts is
followed by an inflammatory reaction, often of a
granulomatous type, involving macrophage and
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giant-cell infiltration. The foreign-body inflam-
matory reaction leads to an endothelial reaction,
causing intimal proliferation and intravascular
fibrosis of the affected vessels. The entire pro-
cess of cholesterol crystal embolism and vascu-
lar reaction results in narrowing or obliteration
of the lumen.1,17,24 These pathological changes
result in tissue effects distal to the cholesterol
crystal emboli and include ischemia and, rarely,
infarction, depending on the extent of organ
involvement.
On the basis of ultrastructural observation of
cholesterol crystal emboli in renal biopsies, Jones
and Iannacone25 divided the changes found into
three phases. The early phase consists of fresh
crystal emboli causing endothelial injury and an
early histiocytic response. The intermediate phase
is characterized by a giant-cell reaction and inti-
mal proliferation. The late phase shows the en-
casement of the crystals by histiocytes, more
intimal proliferation, and fibrous tissue forma-
tion.
The sequential changes in the lesions in hu-
man atheroembolism closely resemble those of
cholesterol crystal emboli disease in experimen-
tal animals. Flory8 first attempted to reproduce
cholesterol crystal emboli in rabbits. Cholesterol
crystal embolic lesions were identified in the
pulmonary vessels. At 24 hours, there was a
marked leukocytic response surrounding the arte-
rial lesion; at 7 days, sequestration of the choles-
terol crystals by foreign-body giant cells and scar
was found. Snyder and Shapiro26 amplified these
observations. Cholesterol clefts could be identi-
fied in the small pulmonary arteries of rabbits 1
day after the injection. By 3 days, there was
panarteritis with numerous eosinophils; the in-
tima was hyperplastic, and foreign-body giant
cells were also found around the crystals. By 12
days, intimal fibrosis and sequestration of the
crystal by foreign-body giant cells occurred. No
further changes were observed at 160 days. This
experimental work showed the persistence of
cholesterol crystal emboli for long periods, con-
firming that cholesterol crystals, insoluble in
body fluids and not removable by phagocytosis,
may act as a permanent foreign body. In confor-
mity with these findings, Gore et al27 found that
the cholesterol crystals may be shown in rats 9
months after the acute event, confirming that
they remain unadsorbed.
Finally, the time course of the renal tissue
reaction was studied by Warren and Vales,28 who
injected atherosclerotic material into rabbit renal
arteries. In the first days, an occlusive thrombus
was noted that incorporated cholesterol crystals,
debris, platelet aggregates, and fibrin. This was
followed by partial temporary resolution of the
thrombus, with partial recanalization of the lu-
men. In a final late phase, identified from 5 days
to 1 month, extensive fibrosis around cholesterol
crystals was noted. Thus, experimental and hu-
man studies provide a picture of an evolving
vascular lesion. The rapidity of the fibrotic pro-
cess is a point deserving consideration and seems
to be caused by the intrinsic properties of athero-
sclerotic material, which is highly thrombogenic
and may also trigger complement activation.
EPIDEMIOLOGICAL CHARACTERISTICS
The syndrome of renal cholesterol crystal em-
bolism usually affects elderly men with a history
of diffuse atherosclerosis.1-3 In the largest reports,
mean age varied from 66 to 70 years (range, 45
to 84 years).2,3,11-14 The disease is more fre-
quently diagnosed in men than women,1-3,11-14
which may be explained by a difference in the
prevalence of atherosclerosis between these
groups.2 A review of the literature regarding the
racial incidence of atheroembolism suggests that
it predominately affects whites.29 Because blacks
appear to have an increased prevalence of athero-
sclerosis compared with whites, it has been sug-
gested that this diagnosis may be underrecog-
nized in patients with dark skin.2
The true incidence of atheroembolic renal dis-
ease is difficult to estimate. Recent studies showed
that this entity is not a rare event in everyday
clinical practice. Mayo and Swartz14 reviewed
402 consultation charts in a single institution,
suggesting that the incidence of clinically detect-
able atheroembolism amounted to at least 4% of
all inpatients examined. Belenfant et al12 re-
ported that 3% of 2,102 patients admitted to their
tertiary renal intensive care unit over a 12-year
period were diagnosed as having renal atheroem-
bolism. Our series includes 52 cases of atheroem-
bolic renal disease identified at our institution
over a 10-year period. The frequency of this
diagnosis increased during the period, and in the
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last 2 years, we estimate encountering cases of
atheroembolism as frequently as once monthly.
However, these retrospective surveys do not
allow incidence calculation of atheroembolic re-
nal disease because patients with severe athero-
embolic renal failure are usually overrepre-
sented, representing the “tip of the iceberg.”
Estimates of renal cholesterol crystal embolism
frequency are mainly derived from autopsy or
renal biopsy examinations and case series of
angiographic studies (Table 2). Retrospective
autopsy or biopsy studies may exaggerate the
frequency of the disease because they may detect
subclinical cases. Conversely, the incidence of
atheroembolic renal disease in clinical studies
appears to be much less than that observed in
autopsy and biopsy studies. However, in these
studies, clinically significant atheroembolism has
probably been underestimated because of short-
term follow-up. Among unselected series of au-
topsies, the frequency of atheroemboli is gener-
ally considered to be low, ranging from 0.31% to
2.4%.16,30,31 However, autopsy studies performed
in selected populations, such as older subjects
and patients who died after aortic surgery and
aortography, have reported greater frequencies
of cholesterol crystal embolism, varying from
12% to 77%.15,16,20,32
Systematic studies of the antemortem diagno-
sis of renal cholesterol crystal embolization in
humans are very few. Jones and Iannacone25 and
Lie24 found a 1% incidence of renal atheroem-
boli in series of 755 and 4,580 consecutive renal
biopsies, respectively. However, when older sub-
jects are considered, the prevalence is greater. In
a survey of 334 renal biopsies performed on
patients aged 65 years or older, Preston et al33
found 14 cases (4.2%) of cholesterol crystal
embolism. In 1992, Stone and Fogo34 found a
prevalence of cholesterol crystal embolism of
0.8% in 1,219 consecutive renal biopsies; how-
ever, in 91 elderly patients, a prevalence of 5.5%
was documented.34 Estimates of the incidence of
renal atheroembolic disease after aortic catheter-
ization are varied and appear to be much less
than those observed in autopsy and biopsy stud-
ies. The four largest catheterization studies of the
literature, involving 24,897 patients, cited an
incidence less than 0.2% (range, 0.06% to
0.18%).5,21,35,36 However, it remains difficult to
quantify the magnitude of clinically significant
angiography-associated atheroembolism because
Table 2. Incidence of Renal Atheroembolism
Reference Incidence (%) Population Under Study
Autopsy studies
Kealy16 1 Unselected series (n 5 2,126)
Cross30 2.4 Unselected series (n 5 372)
Moolenar and Lamers31 0.31 Unselected series (n 5 89,075)
Flory8 12.3 Severe aortic atherosclerosis (n 5 57)
1 Moderate aortic atherosclerosis (n 5 147)
0 No aortic atherosclerosis (n 5 63)
Thurlbeck and Castleman15 77 Aortic surgery (n 5 22)
31 Nonoperated aneurysm (n 5 42)
15.8 Severe atherosclerosis (n 5 38)
0 Minimal atherosclerosis (n 5 44)
Gore and Collins32 17.6 Subjects .60 y (n 5 34)
Ramirez et al20 27 Cardiac catheterization (n 5 71)
Kidney biopsy studies
Jones and Iannacone25 1 Consecutive biopsies (n 5 755)
Lie24 1 Consecutive biopsies (n 5 4,580)
Preston et al33 3.4 Subjects $65 y (n 5 334)
Stone and Fogo34 0.8 Consecutive biopsies (n 5 1,219)
5.5 Elderly subjects (n 5 91)
Angiographic studies
Drost et al35 0.15 Cardiac catheterization (n 5 4,578)
Colt et al5 0.18 Cardiac catheterization (n 5 3,733)
Johnson et al21 0.06 Coronary angioplasty (n 5 1,579)
Frock et al36 0.1 Angiography (n 5 14,998)
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the majority of the studies did not search the
disease systematically, which can manifest weeks
to months after the procedure.
PATHOLOGICAL CHARACTERISTICS
The histological features of renal cholesterol
crystal embolization are highly characteris-
tic.1-3,25 The hallmark of the condition is an
occlusion of the lumen of small arteries by athero-
sclerotic material. Because the lipids are dis-
solved by the techniques used to prepare the
tissue for histological examination, the choles-
terol crystals may be identified by the presence
of needle-shaped spaces, which appear empty in
routine histological sections. Thus, clefts are
found that remain after cholesterol has dissolved
during fixation. Renal histological examination
shows characteristic, biconvex, needle-shaped
clefts in vessels between 50 and 200 mm in
diameter (arcuate and interlobular arteries). Some
vessels are completely obliterated; others show a
residual lumen. Rarely, the cholesterol crystals
lodge in the afferent arteries and glomeruli. The
clefts occasionally may be seen singly in a ves-
sel; usually, they consist of clusters of elongated
biconvex needle-shaped crystals lying parallel to
one another. However, in frozen sections, the
crystals are highly birefringent and give positive
histochemical reactions for lipids.1-3 In acute
lesions, the crystals are embedded in lipid-rich
amorphous debris and blood clot; an inflamma-
tory response characterized by polymorpho-
nuclear leukocytes and eosinophils may be seen
transiently. At later stages, foreign-body giant
cells, endothelial proliferation, and fibrous tissue
surrounding the crystals are found, leading to
luminal obliteration.25 Occlusion of vessels 150
to 200 mm in diameter can account for the
changes in renal parenchyma. Numerous foci of
patchy, irregular atrophy of the renal paren-
chyma and occasional areas of ischemic infarc-
tion may be seen. In the involved areas, glo-
meruli show various degrees of obsolescence or
ischemic retraction of the tuft. Many tubules
show atrophic changes from slight to severe;
areas of acute tubular necrosis may also be
present. The interstitium appears to be enlarged
by diffuse fibrosis.1-3
Sporadically, other renal histological features
have been described, such as necrotizing glomer-
ulonephritis and crescenteric changes.2,3 In addi-
tion to the changes caused by vascular occlusion
by cholesterol crystals, other renal parenchymal
changes related to associated underlying dis-
eases may be found. Because the patients with
atheroembolism usually have diffuse atheroscle-
rosis and hypertension, varying degrees of
nephroangiosclerotic lesions may be seen.37,38 A
picture of glomerulosclerosis secondary to diabe-
tes mellitus, which is considered a risk factor for
the disease, may be superimposed.13 The find-
ings on gross examination of the kidneys reflect
the previously mentioned parenchymal changes.
Both kidneys are usually reduced in size and
have a rough granular surface with wedge-
shaped vascular scars. Numerous patchy, yellow-
white, wedge-shaped, atrophic areas of ischemia
are surrounded by zones of unaffected tissue. On
gross inspection, only occasional areas of acute
infarcts may be seen.1-3 In addition to the kidney,
atheroemboli have been found in many anatomic
sites, including skin, muscles, spleen, gastrointes-
tinal system, heart, brain, bone, prostate, bladder,
penis, testes, and spinal cord.1-3
CLINICAL FEATURES
The clinical consequences of cholesterol crys-
tal embolization vary considerably. Patients may
be completely asymptomatic when the diagnosis
is made coincidentally at renal biopsy, or they
may present with a distinct clinical syndrome,
ranging from a cyanotic toe to a multiorgan
systemic disease that can mimic other systemic
diseases1-6,11-14 (Table 3). The distribution of end-
organ damage depends on the anatomic location
of the original atherosclerotic plaques and the
extent of organ involvement. For instance, cho-
lesterol crystal embolization from carotid artery
plaques leads to clinical involvement confined to
the retinal and cerebral circulation. However,
when the source of the atheroemboli is in the
thoracic aorta or, more commonly, the abdominal
aorta, the central nervous system, visceral or-
gans, and extremities may be involved. Only the
lower extremities are involved if the site is below
the renal arteries.
From a clinical point of view, cholesterol
crystal embolism is a puzzling event, and athero-
embolic renal disease is part of a multisystem
disease. Moreover, individuals at risk for renal
cholesterol crystal embolism commonly have
other chronic illnesses causing renal failure, such
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as hypertension, renovascular disease, and diabe-
tes mellitus. Finally, patients at risk for atheroem-
bolic renal disease usually have multiple risk
factors for atherosclerosis and almost always
have symptomatic atherosclerosis.1-6,11-14 In our
series of 52 patients with atheroembolic renal
failure, at the time of the diagnosis, all but 1
patient had one or more of the following risk
factors and/or prior medical problems: hyperten-
sion (88%), diabetes mellitus (19%), tobacco use
(100%), coronary artery disease (67%), periph-
eral vascular disease (56%), cerebrovascular dis-
ease (31%), and aortic aneurysm (31%). A his-
tory of chronic renal failure was documented in
29 patients (56%). Renal artery stenosis, diag-
nosed by duplex sonography and/or renal angiog-
raphy, was documented in 12 patients (23%).
Renal Involvement
The kidney is a frequent target organ for
cholesterol crystal embolization. Although a small
nonsignificant cholesterol crystal embolism can
occur in kidneys and be clinically silent, renal
clinical manifestations are found at presentation
or during the course of the clinical illness in
approximately 50% of the patients.1-3 In patients
with the disease occurring after angiographic and
vascular surgical procedures, the interval from
the inciting event to the onset of renal symptoms
may vary greatly. Some patients have immediate
clinical features, but in others, the onset can be
more insidious, with a delay of weeks or months
between the precipitating event and clinical fea-
tures.1-6,11-14 In 17 patients who developed athero-
embolization after an arteriographic procedure,
Frock et al36 found the mean interval between the
inciting event and diagnosis of atheroembolic
renal disease to be 5.3 weeks.
Cholesterol crystal emboli may give rise to a
spectrum of degrees of renal functional impair-
ment. Some patients show only a moderate loss
of renal function; in others, severe renal failure
requiring dialysis ensues.1-6 Clinically, three types
of atheroembolic renal disease have been de-
scribed. In the first type, renal impairment may
be abrupt and have a sudden onset. This acute
form of renal failure, usually associated with
evidence of cholesterol crystal embolization else-
where, develops a few days after the inciting
event and is considered to be the consequence of
a massive embolization.
The second type of atheroembolic renal dis-
ease, the most frequently observed, is character-
ized by a subacute time course, probably ex-
plained by the foreign-body reaction or the cyclic
occurrence of cholesterol crystal emboli show-
ers. In this setting, renal impairment occurs in a
Table 3. Clinical and Laboratory Features of Atheroembolic Renal Disease in the Five Largest Case Series
Reference
Fine et al2 Lye et al3 Thadhani et al11 Belenfant et al12 Scolari et al*
No. of patients 221 129 52 67 52
Spontaneous form (%) 69 40 0 4 21
Iatrogenic form† (%) 31 60 100 96 79
Radiology procedure (%) 18 43 96 85 50
Cardiovascular surgery (%) 9 5 41 36 15
Anticoagulation (%) 14 13 37 76 21
Skin lesions (%) 35 43 50 90 96
GI involvement (%) 10 10 29 33 8
CNS involvement (%) — 12 23 4 8
Retinal emboli (%) 6 10 25 22 8
Eosinophilia (%) 73 71 22 59 62
Outcome
CRF requiring dialysis (%) 28 40 44 61 35
Recovery from dialysis dependence (%) — 21 26 32 27
1-Year mortality rate (%) 81 64 87 23 31
Abbreviations: GI, gastrointestinal; CNS, central nervous system.
* Current study.
† Some patients experienced more than one triggering factor.
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stepwise fashion. Usually, there is an increase in
creatinine level a few weeks rather than a few
days after the procedure, and there may be a
plateau phase before a further increase in creati-
nine level occurs. In some patients, it is difficult
to determine the exact onset of renal impairment
because they are already azotemic when they
first come under observation.13
In addition to these acute and subacute sce-
narios, usually after triggering events, a third
clinical form, renal atheroembolism, has been
observed. It presents as chronic and stable renal
impairment associated with the clinical presenta-
tion of nephroangiosclerosis and/or ischemic ne-
phropathy. This asymptomatic form, frequently
spontaneous, may be missed if renal biopsy is
not performed; sometimes, even histological ex-
amination may be unconclusive because choles-
terol crystal embolization is a patchy process. In
this setting, the true role of cholesterol crystal
embolism in the progression of renal failure is
difficult to assess because they usually cocluster
with angiosclerotic and atherosclerotic renal le-
sions.37,38 The renal outcome for patients with
atheroembolic renal disease may be variable;
some patients deteriorate or remain on dialysis,
some improve, and some remain with chronic
impairment. In both the acute and subacute sce-
narios, dialysis may be required in 28% to 61%
of the patients.2,3,11-13 In early reports, the renal
outcome was described as quite dismal, with
progression over weeks to months to end-stage
renal failure.2,3 However, more recent experi-
ences suggest less inexorable deterioration, with
a possibility for spontaneous recovery of renal
function in approximately one third of the pa-
tients, even after variable periods of dialytic
support.11-13 The recovery of renal function is
probably caused by several factors, such as rever-
sal of inflammation, resolution of acute tubular
necrosis in ischemic areas, and hypertrophy in
surviving nephrons.
In our series, the three major clinical forms of
renal atheroembolic disease were found. In 18
patients (35%), the mode of presentation of renal
disease was sudden and acute renal failure that
occurred 3 to 7 days after the inciting event
(angiography). In 29 patients (56%), a subacute,
prolonged, and insidious clinical course was ob-
served, and renal function deteriorated in a step-
wise fashion over 2 to 6 weeks. Five patients
(9%) with a spontaneous form of the disease had
chronic and stable renal impairment at time of
diagnosis. A spectrum of severity of renal impair-
ment was observed. Uremic signs and symptoms
requiring dialytic therapy occurred in 18 patients
(35%); 10 patients were treated by hemodialysis
and 8 patients, by peritoneal dialysis. Thirteen
patients remained on maintenance dialysis
therapy. Five patients (3 patients treated by peri-
toneal dialysis; 2 patients, hemodialysis) recov-
ered sufficient renal function to stop dialysis
over an average period of 8 months. In 4 of these
patients, dialysis was restarted after few months
to control volume overload and/or uremia. At the
end of follow-up, only 1 patient was on conserva-
tive management without dialysis. In 34 patients
(65%), the decline in renal function was limited
and followed a conservative course. In 32 of
these patients, renal function slowly improved or
stabilized; in 2 patients, a progressive deteriora-
tion of renal function reaching end-stage renal
failure requiring dialysis was observed during
follow-up.
Renal atheroembolization is often associated
with accelerated, poorly controlled hyperten-
sion.1-6 In a review by Lye et al,3 48% of 129
reported patients had severe, accelerated, and/or
labile hypertension. Malignant hypertension has
also been described.39 Potentiation of the renin-
angiotensin system is the suggested mechanism
for hypertension, in which repeated showers of
cholesterol crystals are believed to obstruct the
renal arterioles, leading to renal ischemia. In our
series, a history of antecedent hypertension, exac-
erbated by the cholesterol crystal embolic dis-
ease, was present in 46 patients (88%); in 6
patients (12%), hypertension appeared de novo
after renal atheroembolization. Finally, frank re-
nal infarction with flank pain or gross hematuria
is an unusual clinical presentation of renal ath-
eroembolization, and it has rarely been de-
scribed.1,6
Cutaneous Manifestations
Among extrarenal findings, the most common
is the skin. Cutaneous features most often found
are purple toes and livedo reticularis. Typically,
the purple/blue toe syndrome presents as the
sudden appearance of a small, cool, cyanotic,
and painful area of the foot (usually a toe). The
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lesion is tender to touch, usually bilateral, and
may progress to ulceration, distal digital infarcts,
and gangrene. In the majority of patients, the
presence of digital cyanosis is characterized by
well-preserved peripheral pulses.1-6 Livedo reticu-
laris is also a frequent skin lesion. This consists
of a blue-red mottling of the skin in a netlike
pattern, most likely caused by obstruction of
small arteries, capillaries, or venules in the deep
dermis. It is often seen on the feet, legs, buttocks,
and lumbar region. Other dermatologic manifes-
tations include nodules, which appear as the
result of an inflammatory reaction surrounding
cholesterol crystals, purpura, and petechiae.1-3
In a review, Falanga et al40 found that cutane-
ous manifestations were the most common signs
of systemic cholesterol crystal embolization and
occurred in approximately 35% of the patients.
Livedo reticularis was the most common skin
lesion, followed by gangrene, cyanosis, ulcer-
ation, nodules, and purpura. In the four largest
reports, cutaneous manifestations occurred in
35% to 90% of the patients with cholesterol
crystal embolization.2,3,11,12 The greater inci-
dence of cutaneous lesions reported in recent
studies could be explained by close monitoring
of the patients during the time course of the
disease.
In our series, cutaneous lesions, which usually
occurred before renal symptoms, occurred in
96% of 52 patients. The most frequent skin
lesions were cyanosis of the toes (79%), livedo
reticularis of the lower limbs and abdomen (38%),
and gangrene of the extremities (15%); two pa-
tients also showed ulcerations of the scrotum and
penis. The two patients without cutaneous le-
sions had a spontaneous form of renal atheroem-
bolization presenting as chronic and stable renal
impairment.
Gastrointestinal Involvement
Atheroemboli to the gastrointestinal tract are
not uncommon, representing an important and
often unsuspected cause of abdominal manifesta-
tions. Involvement of the digestive system varies
from 18.6% to 48%, depending on the series
cited, and may occur at any site along its length,
producing many, often misleading, presenta-
tions.41 Usually, the prognosis of patients with
gastrointestinal disease is poor; the overall death
rate is high. Thurlbeck and Castleman15 first
observed atheroemboli in the surgically resected
stomach of an 80-year-old woman. However,
they attributed little significance to this finding.
The most common mode of presentation of
cholesterol crystal embolism to the bowel is
hemorrhage and abdominal pain.1-3,42-44 Gastroin-
testinal bleeding most often results from superfi-
cial mucosal ulcerations, erosions, or mucosal
infarcts. Clinical presentation may range from
occult blood loss and melena to bloody diarrhea,
depending on the site and extent of the lesions.
Abdominal pain may be caused by noninfarctive
ischemia, also inducing malabsorption and diar-
rhea, or by fibrous stricture with bowel obstruc-
tion caused by tissue-repair reactions after re-
peated showers of atheroemboli. Less frequently,
intestinal infarction and perforation involving
both the large and small bowel have been de-
scribed. Cholesterol clefts may be found in an-
giodysplastic lesions, suggesting an etiologic re-
lationship between them caused by ischemic
degenerative changes of the vessel wall. Pseu-
dopolyp formations resulting from tissue-repair
reaction have also been described. Pancreatitis is
a rare presentation, although the pancreas is a
frequent site of emboli.1-3,41,44 Clinically, overt
hepatitis is rare, and it is characterized by focal
liver cell necrosis downstream of lodged arterio-
lar cholesterol crystals, with an increase in
transaminase levels.44 Acalculous necrotizing
cholecystitis has been reported rarely as a compli-
cation of atheroembolism.42-44
Intestinal symptoms, consisting mostly of nau-
sea, emesis, abdominal pain, diarrhea, and gastro-
intestinal bleeding, were present in 10% to 33%
of the patients in the largest patient series pub-
lished.2,3,11,12 In our series, gastrointestinal in-
volvement manifested as abdominal pain, diar-
rhea, and gastrointestinal bleeding in 16% of 52
patients. Fiberoptic endoscopy and biopsy docu-
mented ischemic colitis in 4 patients and gastric
bleeding in 3 patients at the site of atheroembo-
lism. One patient had atheroembolic intestinal
infarction.
Nervous System Manifestations
Cerebral cholesterol crystal embolism may
be associated with various symptoms, such as
transient ischemic attacks, cerebral infarction,
amaurosis fugax, paralysis, confusional states,
and gradual deterioration of neurological func-
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tion.1-3,45-47 In the largest case series, neurologi-
cal manifestations occurred in 4% to 23% of the
patients with renal cholesterol emboli syn-
drome.2,3,11,12 In our series, cerebral involvement
that included transient ischemic attacks, strokes,
and changes in level of consciousness was found
in 8% of 52 patients.
However, in clinical studies, a definite diagno-
sis of atheroemboli in the brain is difficult to
make, and it ultimately depends on evidence of
cholesterol crystal embolization to other organs.
To evaluate the role of cholesterol crystal emboli
in the development of cerebral ischemic events,
autopsy-proven cases need to be analyzed. Ma-
suda et al48 described 15 autopsy cases with
cerebral atheroemboli, identifying two major
forms of cerebral cholesterol crystal emboli. The
first was characterized by single or multiple
cortical infarcts corresponding to the border zones
between two main cerebral arterial territories; in
this setting, atheroemboli occluded the leptomen-
ingeal arteries with diameters less than 300 mm.
The second form consisted of arterial territorial
infarcts located in the territories irrigated by one
of the major cerebral arteries or their branches;
this occurred when clusters of cholesterol crys-
tal, forming larger emboli, tended to occlude
larger arteries. Involvement of the spinal cord
artery, which can lead to lower-extremity paraly-
sis, is considered rare.49 However, subclinical
involvement of the spinal cord artery may be
greater. In an autopsy series, Slavin et al50 docu-
mented cholesterol crystal emboli in spinal and
sacral cord arteries in 43% of 28 patients with
evidence of visceral atherosclerotic disease.
Finally, the retina is a frequent target organ of
atheroembolism, providing a unique opportunity
to observe cholesterol crystal emboli.51 Although
carotid artery disease more frequently may be
the origin of retinal cholesterol crystal emboli,
when central nervous system emboli accompany
the more generalized form of the disorder, choles-
terol crystal emboli arise from the proximal part
of the aorta.1-3 The incidence of retinal choles-
terol crystal emboli, responsible for retinal isch-
emic events, varies greatly, ranging from 6% to
25% of the patients, and depends on the propor-
tion of patients in whom the fundi were exam-
ined and the thoroughness of the examina-
tion.2,3,11,12 In a recent series from a university
medical center,14 none of the 11 patients with
renal atheroembolism had been specifically evalu-
ated for this finding, suggesting that the omission
of this noninvasive and diagnostically useful
examination is still frequent. In our series, all 52
patients underwent dilated funduscopic examina-
tion: classic retinal deposits were documented in
4 patients (8%).
Other Extrarenal Manifestations
Showers of cholesterol crystals may occur in
virtually any organ. Myositis and splenic infarcts
are some other rare manifestations of cholesterol
crystal embolism.1-3,41,52 Although uncommon,
atheroembolism may involve the coronary arter-
ies; the usual source is the aortic root or the
proximal coronary artery.53 Recently, cholesterol
crystal embolization to the lung has been de-
scribed, suggesting that atheroembolic renal dis-
ease should be considered a new cause of pulmo-
nary-renal syndrome.54 Subclinical involvement
of the testes, prostate, thyroid, and adrenals has
been reported in autopsy studies.1-3,16,30-32 Non-
specific findings, such as fever, weight loss,
myalgias, and headache, have been reported in a
minority of patients and may suggest a systemic
disease.1-3,11-13
LABORATORY FEATURES
Laboratory features are nonspecific in patients
with cholesterol crystal emboli. However, vari-
ous laboratory tests help establish the diagnosis
of cholesterol crystal embolism. Renal atheroem-
bolic disease is first characterized by elevations
in serum creatinine and blood urea nitrogen
levels. The variable clinical forms of renal in-
volvement (acute, subacute, and chronic) have
been mentioned earlier. Urinary investigation is
generally nondiagnostic because it shows such
nonspecific alterations as mild proteinuria and
microhematuria with hyaline and granular casts.
Hematuria is found in 33% to 40% of the pa-
tients; proteinuria in the nonnephrotic range may
be detected in 50% to 60% of the patients.2,3,11,12
A minority of patients may show nephrotic-range
proteinuria, usually in the absence of overt ne-
phrotic syndrome.55,56 Accelerated hypertension,
a common feature of atheroembolic renal dis-
ease, might explain the nephrotic-range protein-
uria; alternatively, ischemic glomerular injury,
leading to an increased glomerular membrane
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permeability and focal glomerular sclerosis, could
be the major factor in the development of heavy
proteinuria.
In our series, urinalysis showed mild to moder-
ate proteinuria in the majority of patients. The
urinary findings were also unimpressive for vas-
culitis, frequently associated with a nephritic-
type sediment. Nephrotic-range proteinuria was
documented in three patients: two patients had
diabetes and one patient had a previous diagnosis
of immunoglobulin A nephropathy. This sug-
gests that the presence of a different underlying
glomerular disease may represent an additional
possibility to explain the nephrotic-range protein-
uria.
Among the extrarenal laboratory features, eo-
sinophilia appears to be the most common find-
ing. From a review of the literature, Kasinath et
al57 found an 80% incidence of eosinophilia
when adequate white blood cell counts and differ-
entials were reported. Subsequent reports found
an incidence of eosinophilia varying from 14%
to 71%.3,11,12 In our series, hypereosinophilia
was found in 62% of 42 tested patients. The
lower incidence of eosinophilia reported in some
studies could be explained by less close monitor-
ing of white blood cell differential counts during
the time course of the disease. Although persis-
tent eosinophilia has been described, probably
resulting from periodic showers of atheroemboli,
blood eosinophilia is usually transient. Urinary
eosinophilia has also been reported in rare cases.58
Leukocytosis, thrombocytopenia, and anemia
may also accompany eosinophilia.1-3
In an experimental model, Cosio et al59 re-
ported decreased complement levels in rats that
developed renal deposits of cholesterol crystals
after an intravenous bolus of human atheroscle-
rotic material. They also found hypocomple-
mentemia in seven of nine patients with renal
atheroemboli. However, the significance of hypo-
complementemia remains unclear because it is
relatively mild and transient and has not always
been confirmed by subsequent reports. Lye et al3
found hypocomplementemia in only 39% of the
patients with renal atheroemboli. Belenfant et
al12 observed serum complement levels within or
greater than normal range in 46 patients with
renal atheroemboli who had their serum comple-
ment levels measured. In our series, complement
levels were normal in the 25 patients evaluated.
Laboratory markers of acute inflammation,
such as erythrocyte sedimentation rate, serum
C-reactive protein level, and fibrin level, may be
increased in a substantial proportion of cases.
However, because of their nonspecificity, they
lack diagnostic utility.2,12 Autoantibodies to neu-
trophil cytoplasmic antigens (ANCA) were nega-
tive in all 52 patients in our series. Similar results
were reported by Belenfant et al,12 who found
negative ANCA test results in 25 of 26 evaluated
patients.
Laboratory abnormalities may also reflect spe-
cific organ involvement. Hyperamylasemia is
usually caused by pancreatic involvement, an
elevated creatinine phosphokinase level suggests
muscular involvement (myositis), and an in-
crease in serum aspartate aminotransferase, se-
rum alanine aminotransferase, alkaline phospha-
tase, and lactate dehydrogenase levels may reflect
hepatic involvement. Renal infarction, although
rare in the setting of atheroembolization, typi-
cally leads to an increase in serum aspartate
aminotransferase and lactate dehydrogenase lev-
els.1-3 Hypercholesterolemia is a well-known risk
factor for atherosclerosis, of which crystal embo-
lization can be considered a direct complication.
However, the most important studies of atheroem-
bolism usually have not reported serum choles-
terol levels.2,3,11-13 Recently, Mayo and Swartz14
identified hypercholesterolemia as a substantive
risk factor for renal atheroembolization and found
that 27% of their patients had hypercholesterol-
emia. In our series, 63% of 38 patients in whom
total serum cholesterol levels were reported had
values greater than 200 mg/dL.
DIAGNOSIS
From a diagnostic point of view, cholesterol
crystal embolism has challenged physicians for
more than a century. This is likely because ath-
eroembolism is ubiquitous, with random and
variable distributions in the body. Thus, choles-
terol crystal embolism may mimic a variety of
disorders, including systemic vasculitis.1-3
Antemortem diagnosis of renal cholesterol
crystal embolization is difficult and requires a
high index of suspicion. Knowledge of the asso-
ciated risk factors, recognition of its multiple
clinical presentation, and its consideration after
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certain vascular invasive procedures may permit
premortem diagnosis in a significant number of
cases. The typical patient is a white man aged older
than 60 years with a baseline history of hyperten-
sion, smoking, and arterial disease.1-6,11-14 The pres-
ence of a triad composed of a precipitating event,
acute or subacute renal failure, and peripheral
cholesterol crystal embolization strongly sug-
gests the diagnosis. The presence of other compli-
cations of atheroembolism, such as gastrointesti-
nal bleeding and neurological involvement,
should raise the level of suspicion. Among the
laboratory features, helpful clues to the diagnosis
include the presence of eosinophilia57 and an
increase in the markers of acute inflammation, in
association with ANCA negativity.1-3,12
Histological confirmation has traditionally been
considered essential to the antemortem diagnosis
of atheroembolic renal disease.1-6 The confirma-
tory diagnosis is made by means of a biopsy of
the target organs, including kidneys, skin, and
muscle. On occasion, histological confirmation
has been made in less likely target organs, such
as gastrointestinal tissue (Table 4). Renal biopsy
should be considered the most definitive method
of diagnosing atheroembolic renal disease. How-
ever, during the acute phase of disease, many
patients may be too sick to proceed with renal
biopsy: in this setting, the use of an invasive
procedure may not be justified. Moreover, be-
cause cholesterol crystal embolization is a patchy
process, a focal lesion can elude the histological
examination.8
Alternatively, the biopsy of characteristic cuta-
neous lesions may yield a positive diagnosis in
several cases. Skin biopsy is a simple noninva-
sive procedure that can be easily performed.
Falanga et al40 found that histological confirma-
tion of cutaneous atheroemboli was possible in
92% of 24 patients in whom a skin biopsy
specimen was obtained. Random muscle biopsy
from the lower extremities may also have a high
diagnostic yield. In the early reports dealing with
atheroembolism, antemortem diagnosis was fre-
quently based on muscle biopsy.1-6 However,
sensitivity of the muscle biopsy has never been
evaluated; in addition, skin lesions represent a
more easily accessible site. For this and for the
frequency of the peripheral ischemic changes,
skin biopsy specimens should be considered the
best sample of choice for histological diagnosis.
In our series, the diagnosis of cholesterol crys-
tal emboli was confirmed histologically in 41 of
52 patients (79%); it was based on funduscopic
examination showing the presence of retinal cho-
lesterol crystal emboli in 4 patients (8%) and was
made on clinical grounds alone in 7 patients
(13%) presenting with concomitant acute or sub-
acute renal failure, ischemic peripheral changes,
and variable temporal association with a well-
known inciting event. Percutaneous renal biopsy
was performed in only 4 patients (8%). On light
Table 4. Diagnosis of Atheroembolic Renal Disease in the Literature
Reference
Fine et al2 Lye et al3 Belenfant et al12 Scolari et al*
Publication year 1987 1993 1999 2000
No. of patients 221 129 67 52
Clinical diagnosis (%) — 9 24† 21‡
Histological diagnosis (%) 100 91 76 79§
Biopsy
Kidney (%) 7 31 36 8
Skin (%) 8 17 22 52
Muscle (%) 8 21 — —
GI tissue (%) 2 — 18 8
Other (%) 6 — — 2
Autopsy (%) 69 22 — 6
Abbreviation: GI, gastrointestinal.
* Current study.
† In some patients, clinical diagnosis was confirmed by the presence of retinal cholesterol.
‡ Retinal cholesterol emboli confirmed the diagnosis in four patients (8%).
§ In two patients, histological confirmation was obtained by nephrectomy specimens.
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Fig 1. Kidney biopsy
specimen showing choles-
terol crystal emboli (arrows)
occluding the lumen of an
arcuate artery. (Silver methe-
namine stain; original magni-
fication 310.)
Fig 2. Kidney biopsy
specimen showing choles-
terol crystal emboli (arrows)
in an afferent arteriole. (He-
matoxylin-eosin stain; origi-
nal magnification 310.)
Fig 3. Kidney biopsy
specimen showing choles-
terol crystal emboli (arrows)
lodging in the glomerular
tuft. (Hematoxylin-eosin stain;
original magnification 310.)
microscopy, cholesterol crystal emboli consisted
of clusters of elongated, biconvex, needle-
shaped crystals entirely occluding the lumen of
small arteries (Figs 1 and 2). In two cases,
cholesterol crystals were seen in the glomerular
tuft (Fig 3). Varying degrees of arteriosclerotic
lesions and hyalinosis and ischemic changes in
glomeruli and tubuli from slight to severe were
also found. In 1 patient, atheroembolization was
superimposed on the classic lesions of diabetic
nephropathy. In 2 patients with stable and chronic
renal impairment, histological confirmation was
obtained by nephrectomy specimens. The indica-
tion for nephrectomy was renal carcinoma in
both patients. Autopsies were the sole means for
histological diagnosis in 3 patients: cholesterol
clefts were found in the arterioles of both kid-
neys. In addition to the kidneys, material from
necropsy examination showed cholesterol crys-
tal emboli at different sites: stomach, small bowel,
colon, spleen, pancreas, gallbladder, and pros-
tate. Skin biopsy specimens provided the correct
diagnosis in 27 patients (52%), showing choles-
terol clefts in the dermis arterioles of the
involved areas (Fig 4). In 4 patients (8%), histo-
logical confirmation of cholesterol crystal embo-
lization was made in less likely target organs,
such as gastrointestinal tissue (stomach [Fig 5]
and colon) obtained on endoscopy. Interestingly,
in 2 of these patients, atheroemboli were also
found in resected colonic polyps (Fig 6). In 1
patient who presented with an associated hemato-
Fig 4. Small artery in the derma occluded by needle-
shaped clefts (arrows). (Hematoxylin-eosin stain; origi-
nal magnification 310.)
Fig 5. Gastric biopsy
specimen showing choles-
terol clefts (arrows) sur-
rounded by giant cells in the
gastric mucosa. (Hematoxy-
lin-eosin stain; original mag-
nification 310.)
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Fig 6. Cholesterol crystal
emboli (arrows) in a small
artery of a colonic polyp. (He-
matoxylin-eosin stain; origi-
nal magnification 35.)
Fig 7. Bone marrow bi-
opsy specimen showing
cholesterol crystal emboli
(arrows) in the bone marrow
interstitium. (Hematoxylin-
eosin stain; original magnifi-
cation 310.)
Fig 8. Renal allograft bi-
opsy specimen showing
cholesterol crystal emboli
(arrows) in an interlobular ar-
tery. (Trichromic stain; origi-
nal magnification 310.)
logic disorder, the histological diagnosis was
made when the results of an iliac crest bone
marrow biopsy were known, showing choles-
terol crystal emboli (Fig 7).
Regarding the diagnosis, two final points de-
serve consideration. First, in the appropriate clini-
cal setting, ophthalmoscopic examination show-
ing retinal cholesterol crystal emboli may
establish the diagnosis in a significant number of
patients.1-6,11-13 Second, in contrast to the ac-
cepted teaching, in the presence of a specific set
of clinical features (a triad including a precipitat-
ing event, subacute renal failure, and peripheral
cholesterol crystal embolization), the diagnosis
of renal atheroembolic disease may be made
without histological evaluation.9,12-14
DIFFERENTIAL DIAGNOSIS
The symptoms and signs of renal cholesterol
crystal embolization are nonspecific, diverse, and
variable, explaining the notoriety of the disease
as the great masquerader.24 Thus, a number of
clinical entities can simulate cholesterol crystal
embolization. The differential diagnosis should
include contrast nephropathy, small-vessel vascu-
litis, and acute interstitial nephritis.
In the immediate phase after an invasive proce-
dure in which dye has been used, differentiation
from dye-induced nephropathy is important. Con-
trast media–associated nephrotoxicity immedi-
ately follows the radiographic study. There is an
increase in creatinine level a few days after the
procedure; peak creatinine level elevation occurs
approximately 1 week after exposure and returns
to baseline within 10 to 14 days.60 Conversely,
atheroembolic renal damage frequently has a
delayed onset (days to weeks) and a protracted
course; the outcome is often poor, resulting in
progressive renal failure requiring dialysis. When
a fulminant disease develops rapidly after angiog-
raphy, the concomitant cutaneous, neurological,
and gastrointestinal complications usually accom-
pany renal atheroembolic disease.1-6
For the presence of eosinophilia, elevated sedi-
mentation rate, weight loss, fever, and multior-
gan involvement, atheroembolic disease can mas-
querade as systemic vasculitis.1-6,24 The greatest
value in differential diagnosis is the examination
of urinary sediment because vasculitis is usually
associated with a nephritic-type sediment.1 The
introduction of the ANCA test, which has 95%
sensitivity for the diagnosis of vasculitis when
the disease is active, can help differentiate fur-
ther the diagnosis of these two clinical entities.12
In patients presenting with greater diagnostic
confusion, the definitive differentiation of these
two entities will rely on histological examination
of the involved tissue. The presentation of renal
atheroembolism may be indistinguishable from
that of an acute tubulointerstitial nephritis, most
often induced by drug therapy.4 The occurrence
of fever, skin rash, eosinophilia or eosinophiluria
and a sudden deterioration in renal function in
combination with the use of an offending drug is
highly suggestive of acute tubulointerstitial ne-
phritis. However, this diagnosis should be fre-
quently confirmed by renal biopsy.
Finally, subacute bacterial endocarditis, which
may show neurological, renal, and cutaneous
manifestations similar to those of cholesterol
crystal emboli, may be a differential diagnosis,
especially if hypocomplementemia is present.1-4
However, in a patient who harbors occult endo-
carditis as a source of similar lesions, the correct
diagnosis can be suggested by signs and symp-
toms of systemic sepsis and confirmed by echo-
cardiographic examination and blood culture re-
sults.
CHOLESTEROL CRYSTAL EMBOLIC DISEASE
IN RENAL ALLOGRAFTS
Although the clinical features of cholesterol
crystal embolism in the native kidney have been
well delineated, cholesterol crystal embolization
to renal allografts is much less well described.
The finding of atheroemboli in the renal allograft
was first described in 1985 by Cosio et al,59 who
found atheroemboli in transplant nephrectomy
specimens of a patient who experienced oliguria
after cadaveric renal transplantation. Atheroem-
boli causing injury to the renal allograft may
arise from either donor or recipient vessels. When
atheroemboli originate from recipient vessels,
the clinical presentation is that of a late choles-
terol crystal embolic disease, occurring years
after transplantation in a stable graft, often asso-
ciated with the known precipitating factors. Con-
versely, when the clinical presentation is charac-
terized by early cholesterol crystal emboli
associated with initial nonfunction, atheroemboli
are believed to arise from the donor’s aorta.
Since the first description by Cosio et al,59 14
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detailed cases of biopsy-proven cholesterol crys-
tal emboli to renal allografts have been reported
in the literature61-68 (Table 5). Cholesterol crys-
tals originated from the recipient native vascular
tree in five patients who manifested a late choles-
terol crystal embolization with a favorable clini-
cal outcome characterized by recovery of renal
function. In nine patients, atheroemboli to the
allograft were believed to have originated from
the donor aorta; in this setting, atheroemboli
usually are believed to occur during the workup
of a donor, such as coronary arteriography in a
multiorgan donor, or during the procurement
process. Rarely, cholesterol crystal emboli may
occur to the donor kidneys before harvesting,
during the donor’s life. This group with early
cholesterol crystal emboli usually does not show
extrarenal manifestations of atheroemboli and
has a poor prognosis of the graft: six of nine
patients experienced primary allograft nonfunc-
tion requiring nephrectomy, and an additional
patient required nephrectomy for the concomi-
tant presence of acute rejection. Only two pa-
tients with initial nonfunction had spontaneous
recovery of renal allograft function. In one of
these patients, a contributive role of cyclosporine
nephrotoxicity to the patient’s clinical course
was hypothesized.
Recently, we observed a 48-year-old cadav-
eric renal transplant recipient who developed
renal allograft atheroembolization early posttrans-
plantation. The donor was a 62-year-old man
who experienced brain death after an intracere-
bral hemorrhage; his past medical history was
significant for hypertension and tobacco use. At
time of procurement, the donor was found to
have atherosclerotic aortic plaques. The immuno-
suppressive regimen consisted of tacrolimus and
low-dose steroids. Because of initial nonfunc-
tion, a biopsy was performed postoperative day
10. The biopsy findings were consistent with
acute tubular necrosis. No sign of acute rejection
was found. However, one interlobular artery
showed characteristic cholesterol clefts (Fig 8).
No extrarenal manifestation was found, and oph-
thalmoscopic evaluation did not show retinal
cholesterol crystal emboli. Abdominal ultra-
sound did not show aortic atherosclerosis. Hemo-
dialysis, performed without anticoagulation, was
required for 2 weeks, then satisfactory renal
function was gradually established. The source
of the cholesterol crystal emboli in our patient
was probably the donor, and the cholesterol crys-
tal embolization likely occurred at the time of
harvesting. In contrast to the majority of cases
of early cholesterol crystal emboli, our patient
had a spontaneous recovery of renal function,
confirming that atheroemboli at the time of
transplantation may be associated with poten-
tial graft viability.










Source Inciting Event Outcome
Pirson et al61 56 19 y R Streptokinase Functioning graft
Fischman et al68 21 45 1 wk D Procurement Nephrectomy
44 65 3 wk D Procurement Nephrectomy
Aujla et al62 64 2 y R Spontaneous Functioning graft
27 1 wk D Procurement Nephrectomy
Jennings et al63 46 7 y R Trauma Functioning graft
Bellamy et al67 38 59 At Tx D Procurement Nephrectomy
Singh et al66 40 54 1 wk D Procurement Functioning graft
Bolander and Carter65 59 63 1 wk D Angiography or procurement Nephrectomy
43 63 3 wk D Angiography or procurement Nephrectomy
De Takats et al64 58 66 At Tx D Procurement Functioning graft
50 55 1 mon D Procurement Nephrectomy
48 9 y R Anticoagulation Functioning graft
45 15 y R Streptokinase or angiography Functioning graft
Scolari et al* 48 62 2 wk D Procurement Functioning graft
Abbreviations: Tx, transplantation; D, donor; R, recipient.
* Current study.
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However, cholesterol crystal emboli could
have had a contributory role in the ischemic
mechanism leading to acute tubular necrosis, a
clinicopathological picture that recognizes a
multifactorial pathogenesis. Additional cases
of atheroemboli to renal allografts need to be
reported to delineate the true natural history of
the disease. Because the current trend is to
accept older donors and recipients with more
advanced atherosclerotic disease, this entity
will be recognized more frequently in the
future. Thus, cholesterol crystal emboli syn-
drome must be considered part of the differen-
tial diagnosis of primary renal allograft failure.
Finally, care must be taken not only at the time
of organ procurement, but also during the
evaluation of organ donors, to reduce the risk
for atheroemboli.
MANAGEMENT AND OUTCOME
The aim of treatment should be to halt the
progression of tissue ischemia and prevent re-
peated showers of renal cholesterol crystal embo-
lism. At present, no effective treatment is avail-
able for this condition. No controlled studies
show that medical treatment helps after atheroem-
bolism has occurred. Anticoagulants should be
avoided because they may potentiate the prob-
lem.1-6,11-13 A number of antiplatelet drugs have
been tried without success.1,2,37 Anecdotal case
reports have suggested that pentoxifylline may
be beneficial69; however, this has yet to be proved.
Disagreement exists about steroid treatment. A
recent report suggests that steroid therapy might
be useful.12 However, in previous studies, the use
of corticosteroids was associated with 100% mor-
tality.2 Again, it is extremely important to realize
that these are all retrospective analyses, with
several limitations. Thus, no treatment has been
convincingly shown to be effective in altering
the course of the disease.
Because the disease is not rare, treatment
options are urgently needed. Deterioration in
renal function over several weeks suggests an
ongoing cholesterol crystal embolic process.
Thus, strategies should be developed to stabilize
ulcerated or fractured atherosclerotic plaques of
the aorta showering cholesterol crystal emboli
into renal circulation. Whether lipid-lowering
agents are helpful remains uncertain because
only occasional cases of atheroembolism have
responded to lovastatin and simvastatin.70,71 How-
ever, in the context of the emerging evidence of
statin-induced plaque stabilization and regres-
sion,72,73 the possible role of an aggressive lipid-
lowering therapy in the conservative treatment of
cholesterol crystal embolization should be evalu-
ated in a proper prospective study. Medical treat-
ment is mostly symptomatic, and supportive mea-
sures, including dialysis, are appropriate. Both
peritoneal dialysis and hemodialysis have been
shown to be adequate means of management of
these patients.2,3,11-14 Although a particular treat-
ment option is not contraindicated, some investi-
gators suggest that peritoneal dialysis, which
avoids anticoagulation, could be the preferred
treatment modality.74 Conversely, peritoneal di-
alysis should be excluded in the presence of
severe intestinal ischemia and malnutrition.12
Surgical treatment could be the definitive treat-
ment, but it is often not feasible and is associated
with a high death rate.1-6 No randomized trial
supports the effectiveness of preventing future
atheroembolism by surgical repair or removal of
the cholesterol crystal embolic source. Surgery is
rarely indicated because the source of cholesterol
crystals embolization frequently is not certain.
Although we can image the aortic atherosclerotic
lesions through a variety of modalities, we can-
not predict which lesions will embolize choles-
terol crystals. Moreover, patients are usually too
weak for a major surgical intervention, and the
necessary aortic clamping during surgery would
induce a major risk for recurrence.
In a large prospective series, Keen et al75
studied 100 patients with atheroembolic disease,
of whom only 11% had renal involvement and
the rest had only peripheral symptoms. Occlu-
sive aortic iliac disease and small aortic aneu-
rysm were the most common sources for athero-
emboli. Correction of the cholesterol crystal
embolic source was achieved with aortic bypass,
aortoiliac endarterectomy and patch, femoral or
popliteal endarterectomy and patch, and upper-
extremity bypass. The survival rate was 89% at 1
year. All seven early deaths occurred in patients
with major suprarenal aortic disease, six of whom
were undergoing hemodialysis. The investiga-
tors suggested that the source of the cholesterol
crystal emboli can be eliminated surgically with
low mortality or limb loss only when the emboli
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focus is located in the infrarenal aorta. When the
suprarenal aorta is involved, greater mortality
rates are observed, and they appear to be related
to the risk for visceral and renal atheroemboli.
Thus, surgical intervention should be limited to
life-threatening situations, when immediate sur-
vival is at stake.12 Similarly, invasive vascular
radiological procedures should be precluded or
postponed. Prevention is important. The main
recommendation is to restrict the indications of
angiography and surgical procedures as much as
possible in severely atherosclerotic patients.12,37
The availability of new noninvasive diagnostic
tools, such as spiral computed tomographic an-
giography, angiomagnetic resonance, and duplex
ultrasonography, may partially obviate the risk
for catheter-induced embolization.
Patients with atheroemboli have a dismal out-
look. In four different reports, a 1-year mortality
rate ranging from 64% to 87% was noted.2,3,6,11
Causes of death were multifactorial, cardiac,
ruptured aortic aneurysm, central nervous sys-
tem, and gastrointestinal ischemia.1-6,11-14 How-
ever, in a recent study, an aggressive supportive
treatment was associated with a 1-year survival
rate of 79%.12 This aggressive management was
characterized by the avoidance of anticoagula-
tion, good control of hypertension and heart
failure, dialytic therapy, and adequate nutrition;
finally, aortic manipulating procedures were usu-
ally postponed. In our series of 52 patients, the
general therapeutic approach was similar. Antico-
agulant therapy was discontinued. Further inva-
sive procedures were proscribed. The need for
dialysis was evaluated to control both the uremic
state and hypervolemia. Target blood pressure
was 140/80 mm Hg. During the acute phase,
adequate nutritional support was provided by
parenteral nutrition in 4 patients; 3 patients re-
quired an amputation of a portion of the lower
extremity; and 7 patients were treated with pen-
toxifylline without altering the course of disease.
Steroids were not used. The 1- and 2-year sur-
vival rates, estimated using Kaplan-Meier actu-
arial curves, were 69% and 61%, respectively.
Eighteen patients died; 5 patients died during the
acute phase of the disease, and 8 additional
patients died within the first year of follow-up. In
agreement with previous reports, death was most
commonly from cardiac causes, gastrointestinal
ischemia, and stroke. Together, these data and
those of the recent study by Belenfant et al12
suggest that an aggressive therapeutic approach
with patient-tailored supportive measures may
be associated with a favorable clinical outcome.
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